Genetic Technologies P/E 2025

Genetic Technologies Aktienanalyse

What does Genetic Technologies do?

Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Genetic Technologies's P/E Ratio

The Price to Earnings (P/E) Ratio of Genetic Technologies is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Genetic Technologies's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Genetic Technologies is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Genetic Technologies’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Genetic Technologies stock

What is the price-to-earnings ratio of Genetic Technologies?

The price-earnings ratio of Genetic Technologies is currently -1.21.

How has the price-earnings ratio of Genetic Technologies changed compared to last year?

The price-to-earnings ratio of Genetic Technologies has increased by 3,933.33% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Genetic Technologies high compared to other companies?

Yes, the price-to-earnings ratio of Genetic Technologies is high compared to other companies.

How does an increase in the price-earnings ratio of Genetic Technologies affect the company?

An increase in the price-earnings ratio of Genetic Technologies would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Genetic Technologies affect the company?

A decrease in the price-earnings ratio of Genetic Technologies would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Genetic Technologies?

Some factors that influence the price-earnings ratio of Genetic Technologies are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Genetic Technologies pay?

Over the past 12 months, Genetic Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genetic Technologies is expected to pay a dividend of 0 AUD.

What is the dividend yield of Genetic Technologies?

The current dividend yield of Genetic Technologies is .

When does Genetic Technologies pay dividends?

Genetic Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genetic Technologies?

Genetic Technologies paid dividends every year for the past 0 years.

What is the dividend of Genetic Technologies?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genetic Technologies located?

Genetic Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genetic Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genetic Technologies from 1/19/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 1/19/2025.

When did Genetic Technologies pay the last dividend?

The last dividend was paid out on 1/19/2025.

What was the dividend of Genetic Technologies in the year 2024?

In the year 2024, Genetic Technologies distributed 0 AUD as dividends.

In which currency does Genetic Technologies pay out the dividend?

The dividends of Genetic Technologies are distributed in AUD.